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Summary
Background Present treatment strategies to stratify exacerbation risk in patients with chronic obstructive pulmonary 
disease (COPD) rely on a history of two or more events in the previous year. We aimed to understand year to year 
variability in exacerbations and factors associated with consistent exacerbations over time.
Methods In this longitudinal, prospective analysis of exacerbations in the Subpopulations and Intermediate Outcome 
Measures in COPD Study (SPIROMICS) cohort, we analysed patients aged 40–80 years with COPD for whom 3 years 
of prospective data were available, identified through various means including care at academic and non-academic 
medical centres, word of mouth, and existing patient registries. Participants were enrolled in the study between 
Nov 12, 2010, and July 31, 2015. We classified patients according to yearly exacerbation frequency: no exacerbations in 
any year; one exacerbation in every year during 3 years of follow-up; and those with inconsistent exacerbations 
(individuals who had both years with exacerbations and years without during the 3 years of follow-up). Participants 
were characterised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric category (1–4) 
on the basis of post-bronchodilator FEV1. Stepwise logistic regression was used to compare factors associated with 
one or more acute exacerbations of COPD every year for 3 years versus no exacerbations in the same timeframe. 
Additionally, a stepwise zero-inflated negative binomial model was used to assess predictors of exacerbation count 
during follow-up in all patients with available data. Baseline symptom burden was assessed with the COPD assessment 
test. This trial is registered with ClinicalTrials.gov, number NCT01969344.
Findings 2981 patients were enrolled during the study. 1843 patients had COPD, of which 1105 patients had 3 years of 
complete, prospective follow-up data. 538 (49%) of 1105 patients had at least one acute exacerbation during the 3 years of 
follow-up, whereas 567 (51%) had none. 82 (7%) of 1105 patients had at least one acute exacerbation each year, whereas 
only 23 (2%) had two or more acute exacerbations in each year. An inconsistent pattern (both years with and without 
acute exacerbations) was common (456 [41%] of the group), particularly among GOLD stages 3 and 4 patients (256 [56%] 
of 456). In logistic regression, consistent acute exacerbations (≥1 event per year for 3 years) were associated with higher 
baseline symptom burden, previous exacerbations, greater evidence of small airway abnormality on CT, lower 
interleukin-15 concentrations, and higher interleukin-8 concentrations, than were no acute exacerbations.
Interpretation Although acute exacerbations are common, the exacerbation status of most individuals varies markedly 
from year to year. Among patients who had any acute exacerbation over 3 years, very few repeatedly had two or more 
events per year. In addition to symptoms and history of exacerbations in the year before study enrolment, we identified 
several novel biomarkers associated with consistent exacerbations, including CT-defined small airway abnormality, 
and interleukin-15 and interleukin-8 concentrations.
Funding National Institutes of Health, and National Heart, Lung, and Blood Institute.
Introduction
Acute exacerbations of chronic obstructive pulmonary 
disease (COPD) are important events in the disease 
course and their effect should not be underestimated. 
People who have frequent exacerbations have a poor 
quality of life1,2 and more rapid decline in lung function 
compared with those who do not have acute 
exacerbations.3,4 Mortality in the year after an exacerbation 
requiring hospital admission is estimated to be as high 
as 21%.5 Treatment for patients with COPD is expensive, 
 
with US estimates at nearly $50 billion every year 
in 2007;6 much of this cost is related to acute exacerbation 
management. Although therapy can reduce exacerbation 
frequency,7 better treatments are still needed. Accordingly, 
the ability to identify individuals at high risk for the 
purposes of targeted treatment and research is of 
paramount importance.
The ECLIPSE investigators suggested that individuals 
with two or more exacerbations in a given year represent 
a distinct frequent exacerbator phenotype.8 The Global 
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Initiative for Chronic Obstructive Lung Disease (GOLD) 
guide9 to COPD diagnosis and management uses a 
threshold of two or more acute exacerbations in the 
previous year, or at least one hospital admission related to 
an acute exacerbation, to identify individuals at high risk 
of future events (groups C and D). Strategies to prevent 
exacerbations involve targeting of individuals who are at 
high risk of future exacerbations, based on the assumption 
that it is possible to identify a substantial number of these 
patients prospectively. We aimed to assess the value of 
the frequent exacerbator classification as first described 
in ECLIPSE and to understand the factors that are 
associated with consistent exacerbations over time.
Methods
Patients and study design
We did a longitudinal, prospective analysis of acute 
exacerbations of COPD in the Subpopulations and 
Intermediate Outcome Measures in COPD Study 
(SPIROMICS) cohort. SPIROMICS is a multicentre study 
funded by the National Heart, Lung, and Blood Institute 
(NHLBI)10 and designed to identify COPD sub populations 
and to validate intermediate outcome measures. 
Participants were enrolled between Nov 12, 2010, and 
July 31, 2015. Aged 40–80 years at enrolment, participants 
were either healthy never smokers (≤1 pack-year tobacco 
smoking history, prebronchodilator FEV1:forced vital 
capacity [FVC] ratio ≥0·70, prebronchodilator FVC at least 
lower limit of normal,11 and without known lung disease or 
unstable cardiovascular disease) or were current and 
former smokers of more than 20 pack-years with or 
without air flow obstruction (defined as postbronchodilator 
FEV1:FVC ratio of ≥0·70). Participants were identified 
through various means, including care at academic and 
non-academic medical centres, word of mouth, and 
existing patient registries (appendix).10 The SPIROMICS 
protocol was approved by the institutional review boards of 
all participating institutions; all participants gave written 
informed consent.
Participants were characterised by GOLD spirometric 
category 1–4,12 on the basis of spirometric values obtained 
after each of four inhalations of albuterol (90 µg per 
inhalation) and ipratropium (18 µg per inhalation). 
Spirometric tracings were independently reviewed. At 
the initial study visit, extensive data were collected, 
including demographics, symptom severity and quality 
of life, cigarette smoke exposure, spirometry, and 6 min 
walk distance. High-resolution CT was done according to 
the study protocol.13 Details of this baseline assessment 
have been previously published.10
Self-reported exacerbation data in the year before 
enrolment were collected at the baseline visit. Prospective 
exacerbation data were collected every 3 months through 
a structured telephone questionnaire and three annual 
clinic visits. Acute exacerbations were defined as events 
that required health care (ie, office visit, hospital 
admission, or emergency department visit for a respiratory 
flare-up) involving the use of antibiotics or systemic 
corticosteroids, or both. Severe acute exacerbations were 
defined as those requiring a hospital admission or 
emergency department visit. Acute exacerbations were 
managed by the participants’ usual care providers; the 
study did not provide guidance on management.
We measured emphysema and airway wall thickness 
on high-resolution CT imaging by VIDA software (Apollo 
version 2.0.003) using a less than –950 Hounsfield unit 
Research in context
Evidence before this study
We searched PubMed between Sept 1, 2010, and Jan 1, 2016, 
to identify studies that evaluated frequent exacerbators. We used 
the search term “frequent” in combination with “COPD” and 
“exacerbation.” The search was limited to human studies published 
in English. Studies reporting on nine, general population chronic 
obstructive pulmonary disease (COPD) cohorts were identified that 
described frequent exacerbator populations. These studies 
reported a range in prevalence of frequent exacerbators (defined as 
individuals with two or more exacerbations in any 1 year) 
between 14% and 34%. Only one other study, in addition to 
ECLIPSE, was identified that assessed the stability of the frequent 
exacerbator phenotype over time, noting exacerbation frequency 
prior to the study was not a predictor for being a frequent 
exacerbator during the first year of the study.
Added value of this study
In this study, we extend the results of ECLIPSE to a patient 
population with COPD at Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage 1–4. While 
approximately half of all patients (538 [49%] of 1105) had at 
least one acute exacerbation of COPD during 3 years of 
follow-up, two or more acute exacerbations in each year were 
relatively uncommon (23 [2%] of 1105). Significant variation 
from year to year in meeting the frequent exacerbator criteria of 
two or more events per year was noted.
Implications of all the available evidence
Two or more acute exacerbations in the previous year are part of 
the criteria for GOLD ABCD grading criteria and have previously 
been proposed as a key criterion to identify patients for 
therapeutic trials. However, the data in this Article suggest that a 
patient’s acute exacerbation frequency is subject to substantial 
fluctuation. Although exacerbation frequency is an important 
parameter, we show great instability in this measure that 
potentially limits the clinical value of a threshold of more than 
two acute exacerbations in the previous year. As such, this 
criterion might not be the best way to identify individual patients 
at increased risk of acute exacerbations and subsequently classify 
individuals for pharmacotherapeutic decision making.
See Online for appendix
For the SPIROMICS protocol see 
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threshold for emphysema and pi10 (square root of wall 
area of a hypothetical airway with an internal perimeter 
of 10 mm) for airway wall thickening.14 Parametric 
response mapping analysis was done with the Imbio 
Lung Density Analysis software application (version 2.5) 
to distinguish regions of emphysema from regions 
of non-emphysematous gas trapping, indicative of 
functional small airways disease.15
Statistical analysis
Data analysis was done with SAS software (version 9.4). 
We compared participants with 3 years of complete acute 
exacerbation data with the remainder of SPIROMICS 
participants with less than 3 years of follow-up using two-
sample t tests for continuous variables and χ² tests for 
categorical variables. Two regression models were built. 
First, among patients with 3 years of follow-up, stepwise 
logistic regression was used to investigate factors 
associated with having at least one acute exacerbation in 
each of the 3 years (consistent acute exacerbations) versus 
no acute exacerbation in the whole 3 years. Second, 
a stepwise zero-inflated negative binomial model was used 
to assess predictors of exacerbation count during follow-up 
using all patients with available data. Age, sex, race, 
smoking status, clinical centre of recruitment, and FEV1 
percentage predicted were included in all models as 
potential confounders; follow-up time was included as an 
offset in this model. For additional variables, a significance 
level of 0·05 was used as the criterion for entry or deletion 
at each stage. We considered the following additional 
predictors: the COPD assessment test (CAT) score;16 
five measurements obtained from the CT scans (appendix); 
self-reported history of gastro-oesophageal reflux disease; 
history of cardiovascular disease; depression and anxiety 
score from the Hospital Anxiety and Depression Scale 
questionnaire; previous exacer bation history; blood 
eosinophil count; white blood cell count; and 12 biologically 
plausible, circulating bio markers (appendix). We defined 
annualised exacer bation rates as the total number of events 
per person divided by the number of follow-up days for 
that person, multiplied by 365. We assessed for collinearity 
of candidate variables. Many of the imaging variables were 
correlated with themselves and with FEV1 percentage 
predicted. Collinearity can be a concern if it makes model 
estimation unstable, but we did not find that to be the case. 
Stepwise regression was used to select variables with 
independently contributing associations after accounting 
for relevant confounders.
This trial is registered with ClinicalTrials.gov, 
number NCT01969344.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results 
Between Nov 12, 2010, and July 31, 2015, we enrolled 
2981 participants; of these, 1843 had COPD and 1105 of 
these patients had 3 years of complete acute exacerbation 
data (figure 1). Baseline characteristics of participants, 
including the extent of airflow obstruction, are shown in 
table 1. The largest group of patients was at GOLD 2 stage 
(n=494), with relatively equal numbers of patients at 
GOLD 1 (n=274) and GOLD 3 stages (n=250), followed by 
GOLD 4 (n=87; appendix). Due to staggered recruitment 
and protocol-determined termination of data collection, 
738 of patients with COPD did not have 3 complete years 
of exacerbation data (figure 1; appendix). Those with 
complete 3-year exacerbation data were slightly older, less 
likely to be current smokers, had a higher FEV1, and had a 
lower CAT score than patients for whom complete 3-year 
exacerbation data were not available (appendix).
Among the 1105 patients with complete data, 
538 (49%) had at least one acute exacerbation during the 
3 years of follow-up, while 567 (51%) had no exacerbations 
(table 1; appendix). Exacerbation frequency increased 
with worsening airflow obstruction (GOLD category; 
figure 2; appendix). In GOLD categories 3 or 4, most 
individuals had at least one exacerbation during 3 years 
of follow-up (165 [66%] and 73 [84%], respectively). 
Overall, 268 (50%) of 538 individuals who had an acute 
exacerbation had at least one severe exacerbation, as 
identified by emergency department visit or hospital 
admission (appendix). Although exacerbations were 
more often severe in individuals with greater airflow 
obstruction, we noted that even in GOLD stage 1 disease, 
30 (11%) of 274 individuals had at least one severe event. 
Figure 1: Trial profile 





924 GOLD stage 0
5 GOLD stage unclassified
738 excluded
641 less than 3 years of follow-up data
97 incomplete data
2974 available for analysis
1843 with chronic obstructive lung disease
1105 with 3 years of complete prospective data for acute
exacerbations
Furthermore, among GOLD stage 1 patients who had at 
least one exacerbation, 30 (44%) of 68 had at least 
one exacerbation that was severe (appendix).
The patterns of acute exacerbations over 3 years showed 
noticeable year to year heterogeneity (figure 2). The most 
frequent pattern was no exacerbation in any year 
(567 [51%] of 1105 patients). The next most common status 
(456 [41%] of 1105 patients; appendix) was inconsistent 
exacerbators who had some years with exacerbations and 
some years without exacerbations during the 3 years of 
follow-up. 82 (7%) patients had at least one exacerbation 
each year. Only 23 (2%) of 1105 patients had two or more 
exacerbations in each of the 3 years of follow-up and 
would be consistently classified as frequent exacerbators 
by the ECLIPSE criterion.
Assessment of year-by-year exacerbation status showed 
that absence of acute exacerbation over 3 years of follow-up 
was common, and that individuals frequently changed 
status between years (figure 3). These changes in status do 
not simply represent acquisition of acute exacerbations in 
previously exacerbation-free individuals because status 
changed in both directions. We repeated this analysis 
restricted to individuals with GOLD 1–2 and 3–4 stage 
disease and obtained similar results in each instance 
(appendix). Change in exacerbation pattern from year to 
year was a common finding in all GOLD groups.
In an analysis restricted to individuals with GOLD 2–4 
disease, the pattern of inconsistent acute exacerbations 
All patients 
(n=1105)
Patients with 3 years of complete acute exacerbation data








Patients with at least 
one acute exacerbation 
in each of the 3 years 
(n=82, 7%)
Age (years) 66·0 (7·6) 66·7 (7·3) 65·5 (7·8) 64·4 (7·9)
Male sex 631 (57%) 357 (63%) 238 (52%) 36 (44%)
Female sex 474 (43%) 210 (37%) 218 (48%) 46 (56%)
White 924 (84%) 477 (84%) 379 (83%) 68 (83%)
Current smokers 325 (29%) 170 (30%) 137 (30%) 18 (22%)
Postbronchodilator FEV1 (% predicted) 63·27 (22·72) 71·37 (20·84) 56·33 (21·63) 45·91 (18·23)
Acute exacerbation rate in year before enrolment 0·40 (0·87) 0·17 (0·54) 0·55 (0·96) 1·21 (1·40)
Acute exacerbation rate in year 1 0·37 (0·86) 0 (0) 0·50 (0·84) 2·17 (1·38)
One or more acute exacerbations in preceding year 266 (24%) 66 (12%) 149 (33%) 51 (62%)
Two or more acute exacerbations in preceding year 106 (10%) 15 (3%) 65 (14%) 26 (32%)
Severe acute exacerbation requiring admission to 
hospital 
268 (24%) 2 (<1%) 214 (47%) 54 (66%)
COPD assessment test score 14·29 (7·62) 12·05 (7·13) 16·06 (7·29) 19·68 (7·40)
History of gastro-oesophageal reflux disease at baseline 349 (32%) 165 (29%) 155 (34%) 29 (35%)
Chronic bronchitis 232 (21%) 96 (17%) 106 (23%) 30 (37%)
Pi10 3·71 (3·66–3·78) 3·71 (3·66–3·78) 3·71 (3·65–3·78) 3·72 (3·67–3·78)
PRM emphysema 3 (1–13) 2 (0–7) 6 (1–16) 11 (3–25)
PRM functional small airways disease 25 (15–36) 21 (13–31) 31 (18–39) 35 (29–40)
Eosinophil count (×10⁹ per L) 0·2 (0·1–0·3) 0·2 (0·1–0·3) 0·2 (0·1–0·3) 0·2 (0·1–0·3)
White blood cell count (×10⁹ per L) 6·9 (5·8–8·20) 6·7 (5·6–8·10) 7·05 (6·03–8·32) 7·35 (6·3–9·20)
Data are mean (SD), n (%), or median (IQR). COPD=chronic obstructive pulmonary disease. Pi10=square root of wall area of a hypothetical airway with an internal perimeter 
of 10 mm. PRM=parametric response mapping. 
Table 1: Baseline characteristics of study participants
Figure 2: Frequency of acute exacerbations in each of the 3 years in patients with chronic obstructive 
pulmonary disease
Data are the proportion of patients with each category of acute exacerbation frequency, by GOLD stage and in the 






























GOLD stage 1 GOLD stage 2 GOLD stage 3 GOLD stage 4 All stages
C D A B C D A B C D A B C D A B C D
A – No exacerbation in each of the 3 years
B – One or more exacerbations in each of the 3 years
C – Two or more exacerbations in each of the 3 years
D – Inconsistent exacerbations
was most frequent, while 361 (43%) of 831 participants did 
not have any exacerbations during 3 years of follow-up 
(appendix). A distinct minority (21 [3%] of 831 patients) fell 
into a consistent frequent exacerbator category throughout 
the 3 years of follow-up. When the SPIROMICS analysis 
was limited to GOLD 2–4 participants, between years 1 
and 2, 46 (52%) of 88 frequent exacerbators became 
infrequent exacerbators, and 103 (14%) of 743 infrequent 
exacerbators became frequent exacerbators (appendix). 
Although exacer bations were more common in individuals 
with more severe airflow o bstruction, i nconsistent a cute 
exacer bations was the most common status even in GOLD 
categories 3 and 4 (256 [56%] of those with inconsistent 
exacerbations were at GOLD stage 3 or 4), followed by no 
events. Only 13 (4%) of 337 patients in these categories 
were characterised as frequent exacerbators (ie, two or 
more exacerbations per year) during each year of follow-up 
(appendix).
Due to staggered recruitment, some participants were 
recruited later and did not have an opportunity to provide 
3 full years of follow-up. Given subtle baseline differences 
between the 1105 individuals with complete 3 years of 
follow-up data and the 738 for whom data were incomplete, 
we did a similar analysis combining retrospectively 
reported acute exacerbations in the year before study entry 
with the first 2 years of follow-up. With this approach, 
complete data for 3 years (one retrospective and two 
prospective) were available for 1471 patients. Again, the 
pattern of exacerbation frequency was remarkably similar 
to that of the entirely prospective dataset (appendix). Thus, 
in this cohort, most individuals showed either a consistent 
pattern of no acute exacerbation or an inconsistent pattern 
of variation from year to year, with relatively few having 
consistent acute exacerbations each year.
The various clinical characteristics of the patient groups 
with differing patterns of exacerbations during follow-up 
are in table 1 and the appendix. To identify clinical or 
biological characteristics associated with consistent acute 
exacerbations over time, we first compared individuals 
with at least one exacerbation in every year during 3 years 
of follow-up (consistent exacerbators) to those who had 
no exacerbations during follow-up by stepwise logistic 
regression. Variables associated with patients who 
consistently had acute exacerbations included increased 
CAT score, previous acute exacerbations, increased 
CT-defined small airway abnormality, reduced circulating 
interleukin-15 concentrations, and increased interleukin-8 
concentrations (table 2). FEV1 percentage predicted was 
significantly associated with consistent exacerbations 
(table 2). Blood eosinophil count did not predict 
exacerbation group in any analyses (data not shown). 
Visual CT analysis was available in 286 individuals. When 
Figure 3: Stability of acute exacerbation frequency patterns over 3 years of prospective follow-up in patients at Global Initiative for Chronic Obstructive Lung 
Disease stages 1–4
The proportions of participants with no, one, or two or more acute exacerbations in the first year of follow-up are sequentially subdivided by their exacerbation 
frequency in each of the subsequent years. The final column is the proportion, out of all participants, in the final category.





























Exacerbations 1 year post baseline
0 0·2 0·4 0·6 0·8 1·0
Exacerbations 2 years post baseline
0 0·2 0·4 0·6 0·8 1·0










































Two or more exacerbations
tested in the model shown in table 2, visual bronchiectasis 
was not associated with consistent exacerbations (p=0·58).
In a separate analysis, we used a step-wise, zero-inflated 
negative binomial regression model to assess predictors 
of exacerbation rate using all patients with any available 
follow-up data (appendix). As with the logistic model 
assessing associations with consistent exacerbations, 
increased CAT score and previous exacerbation history 
were significantly associated with exacerbation rate 
(appendix). However, in this analysis, female sex, CT-
based air trapping, and increased vascular cell adhesion 
molecule 1 (VCAM-1) concentrations were also associated 
with increased exacerbation rate during follow-up. 
Although FEV1 percentage predicted was associated with 
exacerbation rate in univariate analysis, it was not 
significant in the multivariate analysis (appendix). We 
also ran a subgroup analysis using only frequent 
exacerbators in the zero-inflated negative binomial model 
to identify the relationship between eosinophil count and 
exacerbations. No significant effect for eosinophils was 
noted (p=0·16 full model adjusted for covariates 
[appendix] and p=0·10 for eosinophils alone). In fact, we 
noted a nominally decreasing risk of exacerbations 
(incident rate ratio <1) as eosinophil count increased.
We also did analyses to assess treatment received for 
exacerbations. We assessed the first event among those 
participants who had at least one acute exacerbation in 
the first year and who had complete data for 3 years of 
follow-up. Among the individuals in the inconsistent 
exacerbators group, 38 (32%) of 120 received antibiotics 
only, eight (7%) of 120 systemic steroids only, and 54 (45%) 
of 120 received both antibiotics and systemic steroids. 
Among individuals in the consistent exacerbators group, 
13 (29%) of 45 received antibiotics only, three (7%) of 45 
received steroids only, and 29 (64%) of 45 received both. 
To understand how treatment might vary from event to 
event, we also compared the first treated event in year 1 
with the first treated event in year 2. Significant variation 
in treatment is evident (appendix), but among the 
30 individuals who received both antibiotics and steroids 
for the first event, a large number received both 
treatments again for the second event (n=19, 63%).
Discussion
In a large cohort of highly characterised participants with a 
broad range of lung function impairment, we report that 
the most durable acute exacerbation phenotype is the 
absence of events over a 3-year period, reported in 51% of 
individuals. Among participants who had at least one 
exacerbation over 3 years, exacerbation status was highly 
variable, with only 7% of the cohort consistently having at 
least one exacerbation each year, and only 2% having two or 
more exacerbations in each year. When the analysis was 
limited to GOLD 3 and GOLD 4 status, only 1% of 
participants had two or more exacerbations in every year. In 
multivariate analysis, consistent exacerbations, defined as 
one or more acute exacerbations per year in every year of 
follow-up, were associated with higher CAT score, previous 
history of exacerbations, CT-defined small airway 
abnormality, lower circulating interleukin-15 concentrations, 
and higher circulating interleukin-8 concentrations.
In this study, only 2% of COPD participants had two or 
more exacerbations in each of 3 years of follow-up. Even in 
the more severe ECLIPSE cohort, only 12% of patients 
consistently had two or more exacerbations per year during 
3 years of follow-up.17 Data from the ECLIPSE study 
suggest that patients with a history of two or more 
exacerbations in a previous year represent a relatively 
stable frequent-exacerbator phenotype associated with 
persistently increased inflammation.4 However, between 
years 1 and 2, 210 (39%) of 543 patients changed from 
frequent exacerbators (≥2 acute exacerbations) to 
infrequent exacerbators (0–1 acute exacerbation), while 
221 (17%) of 1289 changed from infrequent exacerbators to 
frequent exacerbators.17 When the SPIROMICS analysis 
was limited to GOLD 2–4 participants, between years 1 
and 2, 46 (52%) of 88 frequent exacerbators became 
infrequent exac erbators, while 103 (14%) of 473 infrequent 
exacerbators became frequent exacerbators (appendix). In 
a smaller study, Brusse-Keizer and colleagues18 also 
reported on exacerbation frequency in a moderate to severe 
COPD cohort of 121 patients. Similar to SPIROMICS, 
between enrolment and year 1, 21 (62%) of 34 frequent 
exacerbators changed to infrequent exacerbators, while 
18 (21%) of 87 infrequent exacerbators changed to frequent 
exacerbators. Although these various populations were 
recruited by separate investigative groups during different 
time periods, necessitating caution in making direct 
comparisons, they show the regularity with which 
individuals change exacerbation categories.
Odds ratio (95% CI) p value
Age 0·82 (0·45–1·50) 0·52
Female sex 1·41 (0·66–3·04) 0·38
Race (white vs other) 0·70 (0·25–2·00) 0·51
Current smoking 0·62 (0·23–1·63) 0·33
FEV1 (% predicted) 0·80 (0·64–1·00) 0·0511
COPD assessment test score 1·11 (1·06–1·17) <0·0001
Acute exacerbations in the 
year before baseline
5·22 (2·38–11·48) <0·0001
PRM functional small 
airways disease
1·51 (1·07–2·14) 0·0197
Interleukin 15 (ng/mL) 0·04 (0·001–0·82) 0·0373
Interleukin 8 (pg/mL) 1·02 (1·00–1·04) 0·0460
Analysis in 394 patients at Global Initiative for Chronic Obstructive Lung Disease 
stages 1–4. Percentage predicted FEV1 was re-parameterised by increments of 
10 percentage points. Model also adjusted for clinical centre of recruitment. When 
only the confounders were used (ie, site, age, sex, race, current smoking, FEV1% 
predicted), area under curve=0·84 (95% CI 0·80–0·89). When the full model was 
used, area under curve=0·92 (95% CI 0·88–0·95). COPD=chronic obstructive 
pulmonary disease. PRM=parametric response mapping.
Table 2: Results of stepwise logistic regression analysis of one or more 
exacerbations during each year of 3 years of follow-up versus no 
exacerbation
In the SPIROMICS cohort, we also show an association 
between consistent acute exacerbations and increased 
functional small airway abnormality and parametric 
response mapping functional small airways disease, as 
detected via recently developed CT metrics. This 
abnormality has also previously been identified a s a 
marker of more rapid lung function decline in COPD.3 
Previous analyses of exacerbations have shown an 
association between segmental level wall thickness 
measured at the fourth generation and exacerbations, 
but parametric response mapping functional small 
airways disease was not included in that analysis.19 In the 
present study, we noted that parametric response 
mapping functional small airways disease was strongly 
associated with consistent exacerbations. Associations 
between low interleukin-15 concentrations and high 
interleukin-8 concentrations and consistent exacerbations 
were also reported. In a a zero-inflated negative binomial 
model, previous acute exacerbations, CAT score, and 
percentage gas trapping on CT (another indirect measure 
of small airway abnormality) were associated with 
exacerbation count, similar to the first model. However, 
several other significant associations emerged, including 
female sex and high levels of circulating VCAM-1. 
Concentrations of interleukin 15 and interleukin 8 were 
not significant i n this alternative m odel nor was FEV1 
percentage predicted. Hence, it is plausible that the 
characteristics of patients with consistent exacerbations 
are different from those of people with inconsistent 
exacerbations. Interestingly, although FEV1 percentage 
predicted was important in the univariate analysis and 
exacerbations were more common in patients with more 
severe airflow obstruction, multivariate analyses yielded 
limited evidence to support an independent contribution 
of this parameter. In two different multivariate analyses, 
FEV1 percentage predicted met the 0·05 significance 
level in one but was not reported to be significant in the 
other. These finding a re probably a f unction of close 
interaction between that parameter and other important 
patient characteristics, such as CT features of COPD.
Ultimately these data have implications for stratification 
of patients both in clinical practice and for research. 
Frequent exacerbator status defined a s t wo o r m ore 
exacerbations in every year is distinctly uncommon; in our 
cohort, only 2% of patients at GOLD 1–4 disease status and 
1% of patients at GOLD 3–4 status were in this category. 
This variability in yearly exacerbation rates could stem 
from failure to consider the multiple triggers that initiate 
exacerbations. Whether an individual patient encounters a 
potent trigger for exacerbation within any given year 
might determine whether or not that individual has an 
exacerbation in that year. Present GOLD stratification 
schema use a history of two or more exacerbations in the 
previous year as one way to identify those at increased risk 
of future events.5 The frequency of these events and their 
consistency across a broad range of patient groups has not 
been thoroughly assessed. Although our data support 
a relationship between previous and future exacerbations, 
they also indicate that exacerbation frequency is highly 
variable over time. Among individuals who inconsistently 
exacerbate, factors extrinsic to the individual, such as 
specific environmental or occupational exposures, might 
have a strong role in exacerbation occurrence, making 
these events difficult to predict.
We acknowledge limitations to this analysis. This 
cohort is not population-based and therefore might be 
biased, as the types of patients evaluated at academic 
centres might differ from the general COPD patient 
population. By design, this cohort also has more mildly 
affected individuals than other cohort studies, such as 
ECLIPSE in which only GOLD 2–4 individuals were 
included. Decisions about treatment of COPD were 
made by the patients’ own physicians and were not 
guided by study protocol. Such analyses also might differ 
based on the types of exacerbations studied. Here, we 
chose to assess moderate to severe events requiring a 
health-care visit. Daily diary data from the Exact Pro 
instrument was captured in a subset of individuals 
and will be assessed in future analyses. Strengths of 
this study, however, include rigorous data collection 
through systematic and frequent contacts with 
participating patients; inclusion of participants exhibiting 
a wide range of disease severity; and detailed phenotyping 
including CT and blood biomarkers.
We report that in a COPD cohort (GOLD 1–4) not selected 
for recent exacerbations, acute exacerbation frequency 
varied greatly from year to year. The two most common 
phenotypes were no exacerbations over 3 years (51% of 
patients) and the inconsistent exacerbator, who changed 
exacerbation status from year to year (41% of patients). 
Those with two or more exacerbations in every year 
represented only approximately 2% of our cohort. We 
identified a group of individuals (7% of patients) who 
consistently exacerbated over time as defined by one or 
more exacerbations every year during 3 years of follow-up. 
Among these individuals, in addition to previous 
exacerbation history and CAT score, we also identified CT-
defined small airway abnormality, low interleukin-15 
concentrations, and increased interleukin-8 concentrations 
as predictors of consistent exacerbation status. Among 
individuals who inconsistently exacerbate, it is plausible 
that factors beyond the individual, such as exposure to 
external triggers, have a strong association with exacerbation 
occurrence, making these events more difficult to predict.
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